Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Antabuse

(Disulfiram)

ApprovedSmall molecule

Disulfiram is a medication used to support recovery from alcohol addiction by creating an unpleasant physical reaction if someone drinks alcohol while taking it. This reaction discourages drinking by causing symptoms like flushing, nausea, vomiting, and chest pain that occur within 10 minutes of alcohol consumption.[2] Antabuse is currently approved and in use across 18 indications[4].[1]

Antabuse is one of 344 small molecule programs targeting Fatigue. It is currently in Approved.

18

Indications

49

Total Trials

9

Active Trials

343

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Alcohol-Related DisordersApproved

OsteosarcomaRecruiting

Germ Cell TumorApproved

HIV-1 InfectionActive, not recruiting

Parasitic InfectionActive, not recruiting

Retinal DegenerationRecruiting

AnxietyRecruiting

Alcohol DependenceActive, not recruiting

Inherited Retinal DystrophyApproved

Non-Small Cell Lung CancerApproved

Alcohol-Related DisordersApproved

Approved

OsteosarcomaPhase 2

Recruiting

Germ Cell TumorApproved

Approved

HIV-1 InfectionPreclinical

Active, not recruiting

Parasitic InfectionApproved

Active, not recruiting

Retinal DegenerationPhase 2

Recruiting

AnxietyPhase 1

Recruiting

Alcohol DependenceApproved

Active, not recruiting

Inherited Retinal DystrophyApproved

Approved

Non-Small Cell Lung CancerApproved

Approved

Showing 10 of 17 indications

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Antabuse

Taxol

Taxotere

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Remeron

OOrganon and Co

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

PD-1 Inhibitors

BBioNTech US Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Sarcomas

NCT05210374

Q4 2027

Phase 1Not yet recruiting

Brain (nervous System) Cancers

NCT07719127

Q1 2028

Phase 2Recruiting

Osteosarcoma

NCT07477457

Q2 2028

Phase 2Not yet recruiting

Rheumatoid Arthritis

NCT07534332

Clinical

Trials by Indication[1]

Glioblastoma5 trials

Bioavailability of Disulfiram and Metformin in Glioblastomas

Terminated·SSahlgrenska University Hospital·Phase 1·NCT03151772·3 enrolled

Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform

Not yet recruiting·OOlympion Medical Center·Phase 2·NCT01777919·32 enrolled

Disulfiram in Recurrent Glioblastoma

Completed·SSahlgrenska University Hospital·Phase 2/3·NCT02678975·88 enrolled

Show 2 more trials

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Completed·WWashington University School of Medicine·Phase 1/2·NCT02715609·35 enrolled

Cocaine Abuse3 trials

Disulfiram for Cocaine Abuse

Completed·UUniversity of Arkansas·Phase 2·NCT00395850·118 enrolled

Clinical Efficacy of Disulfiram in LAAM-Maintained Cocaine Abusers

Completed·YYale University·N/A·NCT00580827·126 enrolled

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Completed·YYale University·Phase 2·NCT00913484·177 enrolled

COVID-192 trials

Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19

Completed·EETICA·Phase 2·NCT04594343·140 enrolled

DISulfiram for COvid-19 (DISCO) Trial

Terminated·UUniversity of California, San Francisco·Phase 2·NCT04485130·11 enrolled

Alcohol Use Disorder2 trials

Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder

Completed·VVirginia Commonwealth University·Phase 1/2·NCT04502589·4 enrolled

The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration

Recruiting·UUniversity of Rochester·Phase 1·NCT06319872·15 enrolled

Interaction2 trials

Interactions Between Cocaine and Ethanol and Disulfiram - 1

Unknown status·NNational Institute on Drug Abuse (NIDA)·Phase 1·NCT00094289·16 enrolled

Disulfiram Interactions With HIV Medications: Clinical Implications

Completed·UUniversity of California, San Francisco·Phase 1·NCT00878306·40 enrolled

31 more indications

Metastatic Melanoma2 trials

Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy

Terminated·UUniversity of California, Irvine·Phase 1·NCT00571116·9 enrolled

Disulfiram in Patients With Metastatic Melanoma

Completed·JJohn P. Fruehauf·Phase 1/2·NCT00256230·7 enrolled

AIN2 trials

A Study of the Relationship Between Disulfiram and Cocaine Self-administration.

Completed·—·Phase 1/2·NCT00729300·52 enrolled

A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts

Withdrawn·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT02134002

Prostate Cancer2 trials

Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT01118741·19 enrolled

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

Terminated·—·Phase 1·NCT02963051·9 enrolled

Glioblastoma Multiforme2 trials

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Terminated·WWake Forest University Health Sciences·Phase 2·NCT03363659·15 enrolled

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

Completed·WWashington University School of Medicine·Phase 1·NCT01907165·21 enrolled

Amyloid1 trial

Disulfiram as a Modulator of Amyloid Precursor Protein-processing

Completed·JJohannes Gutenberg University Mainz··NCT03212599·17 enrolled

Cocaine Dependence1 trial

Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone

Completed·UUniversity of Arkansas·Phase 2·NCT00218608·158 enrolled

Pancreatic Cancer1 trial

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

Terminated·MMayo Clinic·Phase 1·NCT02671890·16 enrolled

Osteosarcoma1 trial

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07477457·45 enrolled

Tics1 trial

Pharmacogenetics of Disulfiram for Cocaine

Completed·—·Phase 2·NCT00149630·93 enrolled

Refractory1 trial

Disulfiram and Cisplatin in Refractory TGCTs.

Completed·NNational Cancer Institute, Slovakia·Phase 2·NCT03950830·12 enrolled

Age1 trial

CBT With Disulfiram and Contingency Management

Completed·YYale University·Phase 1·NCT00350870·181 enrolled

ALS1 trial

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

Completed·UUniversity of California, San Francisco·N/A·NCT01286259·16 enrolled

Alcohol Abuse1 trial

Disulfiram for Cocaine-Alcohol Abuse - 3

Completed·YYale University·Phase 2·NCT00000278

Methamphetamine Dependence1 trial

Open-Label Disulfiram for Methamphetamine Dependence

Completed·UUniversity of Arkansas·Phase 1/2·NCT00731133·15 enrolled

Refractory Solid Tumors1 trial

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver

Completed·UUniversity of Utah·Phase 1·NCT00742911·21 enrolled

HIV infection1 trial

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT01944371·30 enrolled

Alcohol Dependence1 trial

Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence

Completed·FFinnish Institute for Health and Welfare·Phase 4·NCT00435435·243 enrolled

Lyme disease1 trial

Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

Completed·RResearch Foundation for Mental Hygiene, Inc.·Phase 1/2·NCT03891667·11 enrolled

Retinal Degeneration1 trial

Disulfiram for Treatment of Retinal Degeneration

Recruiting·UUniversity of Washington·Phase 1/2·NCT05626920·30 enrolled

Anxiety1 trial

Anxiety During Abstinence in AUD

Recruiting·—·Phase 1·NCT06793488·60 enrolled

Body Weight1 trial

Body Weight Response With Disulfiram in Humans

Unknown status·UUniversidad de Guanajuato·Phase 1·NCT05162001·10 enrolled

Breast Cancer1 trial

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Withdrawn·NNational Cancer Institute, Slovakia·Phase 2·NCT04265274

Multiple Myeloma1 trial

Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma

Terminated·UUniversity of Utah·Phase 1·NCT04521335·2 enrolled

AIDS1 trial

Depot Disulfiram for AIDS and ARC

Completed·SSt. Vincent's Medical Center·N/A·NCT00002065

Alcohol1 trial

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

Completed·UUniversity of Pennsylvania·Phase 2·NCT00142844·208 enrolled

Brain (Nervous System) Cancers1 trial

A Window-of-Opportunity Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High-Grade Glioma

Not yet recruiting·CCase Comprehensive Cancer Center·Phase 1·NCT07719127·20 enrolled

Thoracic Cancer1 trial

MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label Study

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07843537·30 enrolled

Sarcomas1 trial

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Patients With Treatment-Refractory Sarcomas

Recruiting·CCase Comprehensive Cancer Center·Phase 1·NCT05210374·24 enrolled

Rheumatoid Arthritis1 trial

Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis

Not yet recruiting·UUniversity of Oklahoma·Phase 2·NCT07534332·20 enrolled

Breast Neoplasm Female1 trial

Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer

Completed·TThe Institute of Molecular and Translational Medicine, Czech Republic·Phase 2·NCT03323346·9 enrolled

Unspecified1 trial

Neural Mechanisms of Disulfiram Effects

Completed·NNew York State Psychiatric Institute·Phase 4·NCT02735577·7 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ANTABUSE

NDA NDA007883

Sources

References

[1]
ClinicalTrials.gov — 49 trial records for Disulfiram. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Antabuse drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Disulfiram compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Disulfiram. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA007883). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Aldehyde Dehydrogenase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Related News